Types of Ovarian Cancer

Overview

“Cellular Classification,” Ovarian Epithelial Cancer Treatment (PDQ®)(Health Professional Version), National Cancer Institute, March 5, 2008.

“Cellular Classification,” Ovarian Germ Cell Tumors Treatment (PDQ®)(Health Professional Version), National Cancer Institute, December 21, 2007.

“General Information,” Ovarian Low Malignant Potential Tumors Treatment (PDQ®)(Health Professional Version), National Cancer Institute, December 21, 2007.

“What is Ovarian Cancer?” Detailed Guide: Ovarian Cancer, American Cancer Society, January 19, 2008.

“Types of Tumors,” Johns Hopkins Medical Institute, October 18, 2001.

“Primary and Secondary Ovarian Cancer,” Information-About-Ovarian-Cancer.com, March 4, 2008.

“Ovarian Cancer Types,” OncologyChannel, July, 11, 2007.

“Origin of Ovarian Cancer,” http://www.gyncancer.com.

Epithelial Ovarian Cancer

Clear Cell Carcinoma

Kim A, Serada S, Enomoto T, Naka T. Targeting annexin A4 to counteract chemoresistance in clear cell carcinoma of the ovary. Expert Opin Ther Targets. 2010 Aug 2. [Epub ahead of print] PubMed PMID: 20673185.

Matsuura M, Suzuki T, Saito T. Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci. 2010 Aug 1;101(8):1828-33. Epub 2010 May 12. PubMed PMID: 20545695.

Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A; on behalf of the Gynecologic Cancer InterGroup. Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer. Int J Gynecol Cancer. 2010 Aug;20(6):945-952. PubMed PMID: 20683400.

Mabuchi S, Kawase C, Altomare DA, Morishige K, Hayashi M, Sawada K, Ito K, Terai Y, Nishio Y, Klein-Szanto AJ, Burger RA, Ohmichi M, Testa JR, Kimura T. Vascular Endothelial Growth Factor Is a Promising Therapeutic Target for the Treatment of Clear Cell Carcinoma of the Ovary. Mol Cancer Ther. 2010 Jul 27. [Epub ahead of print] PubMed PMID: 20663925.

Gómez-Raposo C, Mendiola M, Barriuso J, Hardisson D, Redondo A. Molecular characterization of ovarian cancer by gene-expression profiling. Gynecol Oncol. 2010 Jul;118(1):88-92. Epub 2010 May 1. Review. PubMed PMID: 20439111.

Duska LR, Horowitz N. Response to: “Ovarian clear cell carcinoma: High risk of venous thromboembolism”. Gynecol Oncol. 2010 Jun 15. [Epub ahead of print] PubMed PMID: 20557925.

Budman DR, Tai J, Calabro A, John V. The histone deacetylase inhibitor panobinostat demonstrates marked synergy with conventional chemotherapeutic agents in human ovarian cancer cell lines. Invest New Drugs. 2010 Jun 9. [Epub ahead of print] PubMed PMID: 20533074.

Matsuura M, Suzuki T, Saito T. Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy. Cancer Sci. 2010 May 12. [Epub ahead of print] PubMed PMID: 20545695.

Lim MC, Park SH, Park SY. Ovarian clear cell carcinoma: High risk of venous thromboembolism. Gynecol Oncol. 2010 May 3. [Epub ahead of print] PubMed PMID: 20444499.

Yamamoto S, Tsuda H, Miyai K, Takano M, Tamai S, Matsubara O. Cumulative alterations of p27-related cell-cycle regulators in the development of endometriosis-associated ovarian clear cell adenocarcinoma. Histopathology. 2010 ay;56(6):740-9. PubMed PMID: 20546339.

Köbel M, Kalloger SE, Huntsman DG, Santos JL, Swenerton KD, Seidman JD, Gilks CB; Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol. 2010 May;29(3):203-11. PubMed PMID: 20407318.

Kajihara H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sado T, Oi H, Kobayashi H. Clear cell carcinoma of the ovary: potential pathogenic mechanisms (Review). Oncol Rep. 2010 May;23(5):1193-203. PubMed PMID: 20372830.

Pourgholami MH, Cai ZY, Badar S, Wangoo K, Poruchynsky MS, Morris DL. Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole. BMC Cancer. 2010 Apr 15;10:143. PubMed PMID: 20398289; PubMed Central PMCID: PMC2873385.

Kuo KT, Mao TL, Chen X, Feng Y, Nakayama K, Wang Y, Glas R, Ma MJ, Kurman RJ, Shih IeM, Wang TL. DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma. Clin Cancer Res. 2010 Apr 1;16(7):1997-2008. Epub 2010 Mar 16. PubMed PMID: 20233889; PubMed Central PMCID: PMC2848895.

Ho CM, Lai HC, Huang SH, Chien TY, Lin MC, Chang SF. Promoter methylation of sFRP5 in patients with ovarian clear cell adenocarcinoma. Eur J Clin Invest. 2010 Apr;40(4):310-8. PubMed PMID: 20486992.

Byron SA, Gartside MG, Wellens CL, Goodfellow PJ, Birrer MJ, Campbell IG, Pollock PM. FGFR2 mutations are rare across histologic subtypes of ovarian cancer. Gynecol Oncol. 2010 Apr;117(1):125-9. Epub 2010 Jan 27. PubMed PMID: 20106510.

Yamaguchi K, Mandai M, Oura T, Matsumura N, Hamanishi J, Baba T, Matsui S, Murphy SK, Konishi I. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes. Oncogene. 2010 Mar 25;29(12):1741-52. Epub 2010 Jan 11. PubMed PMID: 20062075.

Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, Papadimitriou C, Rodolakis A, Vlahos G, Dimopoulos MA. Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer. 2010 Mar 15;116(6):1462-8. PubMed PMID: 20108307.

Nishimura S, Tsuda H, Ito K, Takano M, Terai Y, Jobo T, Kigawa J, Sugiyama T, Yaegashi N, Aoki D. Differential expression of hypoxia-inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. Int J Gynecol Cancer. 2010 Feb;20(2):220-6. PubMed PMID: 20134266.

Suzuki N, Yoshioka N, Uekawa A, Matsumura N, Tozawa A, Koike J, Konishi I, Kiguchi K, Ishizuka B. Transcription factor POU6F1 is important for proliferation of clear cell adenocarcinoma of the ovary and is a potential new molecular target. Int J Gynecol Cancer. 2010 Feb;20(2):212-9. PubMed PMID: 20134265.

Nagaraja AK, Creighton CJ, Yu Z, Zhu H, Gunaratne PH, Reid JG, Olokpa E, Itamochi H, Ueno NT, Hawkins SM, Anderson ML, Matzuk MM. A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol. 2010 Feb;24(2):447-63. Epub 2010 Jan 15. PubMed PMID: 20081105; PubMed Central PMCID: PMC2817607.

Gilks CB. Molecular abnormalities in ovarian cancer subtypes other than high-grade serous carcinoma. J Oncol. 2010;2010:740968. Epub 2009 Dec 30. PubMed PMID: 20069115; PubMed Central PMCID: PMC2804051.

Kim A, Enomoto T, Serada S, Ueda Y, Takahashi T, Ripley B, Miyatake T, Fujita , Lee CM, Morimoto K, Fujimoto M, Kimura T, Naka T. Enhanced expression of Annexin A4 in clear cell carcinoma of the ovary and its association with chemoresistance to carboplatin. Int J Cancer. 2009 Nov 15;125(10):2316-22. PubMed PMID: 19598262.

Cho KR. Ovarian cancer update: lessons from morphology, molecules, and mice. Arch Pathol Lab Med. 2009 Nov;133(11):1775-81. Review. PubMed PMID: 19886711; PubMed Central PMCID: PMC2774913.

Yoshida S, Furukawa N, Haruta S, Tanase Y, Kanayama S, Noguchi T, Sakata M, Yamada Y, Oi H, Kobayashi H. Theoretical model of treatment strategies for clear cell carcinoma of the ovary: focus on perspectives. Cancer Treat Rev. 2009 Nov;35(7):608-15. Epub 2009 Aug 8. Review. PubMed PMID: 19665848.

Yoshioka N, Suzuki N, Uekawa A, Kiguchi K, Ishizuka B. POU6F1 is the transcription factor that might be involved in cell proliferation of clear cell adenocarcinoma of the ovary. Hum Cell. 2009 Nov;22(4):94-100. PubMed PMID: 19874398.

Takano M, Sugiyama T, Yaegashi N, Suzuki M, Tsuda H, Sagae S, Udagawa Y, Kuzuya K, Kigawa J, Takeuchi S, Tsuda H, Moriya T, Kikuchi Y. The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study. Int J Gynecol Cancer. 2009 Nov;19(8):1353-7. PubMed PMID: 20009889.

Mabuchi S, Kawase C, Altomare DA, Morishige K, Sawada K, Hayashi M, Tsujimoto M, Yamoto M, Klein-Szanto AJ, Schilder RJ, Ohmichi M, Testa JR, Kimura T. mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. Clin Cancer Res. 2009 Sep 1;15(17):5404-13. Epub 2009 Aug 18. PubMed PMID: 19690197; PubMed Central PMCID: PMC2743856.

Yamamoto S, Tsuda H, Suzuki K, Takano M, Tamai S, Matsubara O. An allelotype analysis indicating the presence of two distinct ovarian clear-cell carcinogenic pathways:  endometriosis-associated pathway vs. clear-cell adenofibroma-associated pathway. Virchows Arch. 2009 Sep;455(3):261-70. Epub 2009 Aug 5. PubMed PMID: 19655165.

Goodheart MJ, Rose SL, Hattermann-Zogg M, Smith BJ, De Young BR, Buller RE. BRCA2 alteration is important in clear cell carcinoma of the ovary. Clin Genet. 2009 Aug;76(2):161-7. Epub 2009 Jul 28. PubMed PMID: 19656163.

Kobayashi H, Kajiwara H, Kanayama S, Yamada Y, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H. Molecular pathogenesis of endometriosis-associated clear cell carcinoma of the ovary (review). Oncol Rep. 2009 Aug;22(2):233-40. Review. PubMed PMID: 19578761.

Miyazawa M, Yasuda M, Fujita M, Hirasawa T, Kajiwara H, Hirabayashi K, Ogane N, Shimizu M, Asanuma H, Murakami M, Takekoshi S, Mikami M, Osamura RY.  Association of hypoxia-inducible factor-1 expression with histology in epithelial ovarian tumors: a quantitative analysis of HIF-1. Arch Gynecol Obstet. 2009 Jun;279(6):789-96. Epub 2008 Oct 21. PubMed PMID: 18936945.

Maeda D, Ota S, Takazawa Y, Aburatani H, Nakagawa S, Yano T, Taketani Y, Kodama T, Fukayama M. Glypican-3 expression in clear cell adenocarcinoma of the ovary. Mod Pathol. 2009 Jun;22(6):824-32. Epub 2009 Mar 27. PubMed PMID: 19329941.

Kobayashi H, Yamada Y, Kanayama S, Furukawa N, Noguchi T, Haruta S, Yoshida S, Sakata M, Sado T, Oi H. The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary. Int J Gynecol Cancer. 2009 Apr;19(3):471-9. Review. PubMed PMID: 19407577.

Sugiyama T, Kumagai S, Hatayama S. [Treatments of epithelial ovarian cancer by histologic subtype]. Gan To Kagaku Ryoho. 2009 Feb;36(2):187-92. Japanese. PubMed PMID: 19223734.

Kolasa IK, Rembiszewska A, Felisiak A, Ziolkowska-Seta I, Murawska M, Moes J, Timorek A, Dansonka-Mieszkowska A, Kupryjanczyk J. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients. Cancer Biol Ther. 2009 Jan;8(1):21-6. Epub 2009 Jan 17. PubMed PMID: 19029838.

Timmers PJ, Zwinderman AH, Teodorovic I, Vergote I, Trimbos JB. Clear cell carcinoma compared to serous carcinoma in early ovarian cancer: same prognosis in a large randomized trial. Int J Gynecol Cancer. 2009 Jan;19(1):88-93. PubMed PMID: 19258948.

Miyazawa M, Yasuda M, Fujita M, Kajiwara H, Hirabayashi K, Takekoshi S, Hirasawa T, Murakami M, Ogane N, Kiguchi K, Ishiwata I, Mikami M, Osamura RY.  Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma. Pathol Int. 2009 Jan;59(1):19-27. PubMed PMID: 19121088.

Köbel M, Kalloger SE, Boyd N, McKinney S, Mehl E, Palmer C, Leung S, Bowen NJ, Ionescu DN, Rajput A, Prentice LM, Miller D, Santos J, Swenerton K, Gilks CB, Huntsman D. Ovarian carcinoma subtypes are different diseases: implications for biomarker studies. PLoS Med. 2008 Dec 2;5(12):e232. PubMed PMID: 19053170; PubMed Central PMCID: PMC2592352.

Saga Y, Ohwada M, Suzuki M, Konno R, Kigawa J, Ueno S, Mano H. Glutathione peroxidase 3 is a candidate mechanism of anticancer drug resistance of ovarian clear cell adenocarcinoma. Oncol Rep. 2008 Dec;20(6):1299-303. PubMed PMID: 19020706.

Rauh-Hain JA, Penson RT. Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):934-6. Epub 2007 Dec 13. PubMed PMID: 18081793.

Takano M, Sugiyama T, Yaegashi N, Sakuma M, Suzuki M, Saga Y, Kuzuya K, Kigawa J, Shimada M, Tsuda H, Moriya T, Yoshizaki A, Kita T, Kikuchi Y. Low response rate of second-line chemotherapy for recurrent or refractory clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):937-42. Epub 2007 Dec 13. PubMed PMID: 18081792.

Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, Remondo C, Cereda V, Jones JL, Pazdur MP, Higgins JP, Hodge JW, Steinberg SM, Kotz H, Dahut WL, Schlom J. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res. 2008 May 15;14(10):3060-9. PubMed PMID: 18483372; PubMed Central PMCID: PMC2673097.

Itamochi H, Kigawa J, Terakawa N. Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma. Cancer Sci. 2008 Apr;99(4):653-8. Review. PubMed PMID: 18377417.

Crotzer DR, Sun CC, Coleman RL, Wolf JK, Levenback CF, Gershenson DM. Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary. Gynecol Oncol. 2007 May;105(2):404-8. Epub 2007 Feb 9. PubMed PMID: 17292461.

Tan DS, Kaye S. Ovarian clear cell adenocarcinoma: a continuing enigma. J Clin Pathol. 2007 Apr;60(4):355-60. Epub 2006 Oct 3. Review. PubMed PMID: 17018684; PubMed Central PMCID: PMC2001101.

Pectasides D, Pectasides E, Psyrri A, Economopoulos T. Treatment issues in clear cell carcinoma of the ovary: a different entity? Oncologist. 2006 Nov-Dec;11(10):1089-94. Review. PubMed PMID: 17110628.

Zorn KK, Bonome T, Gangi L, Chandramouli GV, Awtrey CS, Gardner GJ, Barrett JC, Boyd J, Birrer MJ. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer. Clin Cancer Res. 2005 Sep 15;11(18):6422-30. PubMed PMID: 16166416.

Köbel M, Xu H, Bourne PA, Spaulding BO, Shih IM; Mao TL et. al. IGF2BP3 (IMP3) Expression Is a Marker of Unfavorable Prognosis in Ovarian Carcinoma of Clear Cell Subtype. Modern Pathology. 2009;22(3):469-475. [Epub 2009 Jan 9].

Glypican-3 expression in clear cell adenocarcinoma of the ovary. Maeda D, Ota S, Takazawa Y et. al. Mod Pathol. 2009 Mar 27. [Epub ahead of print]

Treatments of epithelial ovarian cancer by histologic subtype; Sugiyama T. et. al., Gan To Kagaku Ryoho. 2009 Feb;36(2):187-92 (“Recent molecular studies support the hypothesis that clear cell carcinoma and mucinous adenocarcinoma are refractory cancers that are biologically distinct from serous adenocarcinoma. Treatment of these cancers has not yet been adequately tested, so separate clinical trials are needed for each type. Paclitaxel …combined with carboplatin …is the current gold standard for treating ovarian cancer. Clear cell carcinoma and mucinous adenocarcinoma are less sensitive to a TC regimen than serous adenocarcinoma, and an international randomized trial for clear cell carcinoma is now underway(GCIG/JGOG3017). Targeted therapy is attractive for chemoresistant clear cell carcinoma, thus VEGFR inhibitor(sunitinib), PDGFR inhibitor(sorafenib), m-TOR inhibitor (temsirolimus), and monoclonal antibody(bevacizumab)are being evaluated.”)

Overexpression of Class III {beta}-Tubulin Predicts Good Response to Taxane-Based Chemotherapy in Ovarian Clear Cell Adenocarcinoma, Aoki D, Oda Y, Hattori S, Taguchi KI, Ohishi Y, Basaki Y et. al.; Clin Cancer Res. 2009 Feb 15;15(4):1473-1480 (In a small experimental design study, taxane-based chemotherapy was effective for patients with ovarian clear cell adenocarcinomas who were positive for beta-tubulin III but not for those who were negative for these proteins).

Therapeutic strategy targeting the mTOR-HIF-1alpha-VEGF pathway in ovarian clear cell adenocarcinoma; Miyazawa M, Yasuda M, Fujita M et. al., Pathol Int. 2009 Jan;59(1):19-27.

Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers; Chan JK et. al., Gynecol Oncol. 2008 Jun;109(3):370-6. Epub 2008 Apr 18.

Overexpression of osteopontin in clear cell carcinoma of the ovary: close association with HNF-1beta expression; Kato N, Motoyama T, Histopathology. 2008 May;52(6):682-8. Epub 2008 Apr 2.

Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging; Takano M et. al., Oncol Rep. 2008 May;19(5):1259-64.

Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma; Itamochi H et. al, Can Sci 2008 Apr;99(4):653-658.

Hypomethylation of hepatocyte nuclear factor-1beta (HNF-1beta) CpG island in clear cell carcinoma of the ovary; Kato N, Tamura G, Motoyama T, Virchows Arch. 2008 Feb;452(2):175-80. Epub 2007 Dec 8.

An Up-to-Date Anti-Cancer Treatment Strategy Focusing on HIF-1α Suppression: Its Application for Refractory Ovarian Cancer; Fujita M et. al, Acta Histochem Cytochem. 2007 Dec 18;40(5):139-42.

Potential benefit of Sunitinib in recurrent and refractory ovarian clear cell adenocarcinoma; Rauh-Hain JA, Penson RT, Int J Gynecol Cancer. 2007 Dec 13.

Prognostic analysis of 88 patients with ovarian clear cell carcinoma; Ma SK, Zhang HT, Wu LY, Liu LY, Zhonghua Zhong Liu Za Zhi. 2007 Oct;29(10):784-8.

Galectin-3 may contribute to Cisplatin resistance in clear cell carcinoma of the ovary; Oishi T et. al., Int J Gynecol Cancer. 2007 Sep-Oct;17(5):1040-6. Epub 2007 Apr 12.

Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis; Takano M et. al., Int J Clin Oncol. 2007 Aug;12(4):256-60. Epub 2007 Aug 20.

Irinotecan hydrochloride (CPT-11) and cisplatin as first-line chemotherapy after initial surgery for ovarian clear cell adenocarcinoma; Takakura S et. al., Int Surg. 2007 Jul-Aug;92(4):202-8.

Over-expression of hypoxia-inducible factor 1 alpha in ovarian clear cell carcinoma; Lee S, Garner EI, Welch WR, Berkowitz RS, Mok SC, Gynecol Oncol. 2007 Aug;106(2):311-7. Epub 2007 May 25.

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model, Mabuchi S et. al., Clinical Cancer Research 2007 Jul; 13, 4261-4270.

HER2 overexpression and amplification in advanced ovarian cancer (AOC): Treatment with trastuzumab-A GINECO study, Guastalla JP, J. Clin Oncol 2007 (June Suppl); 25(18S): 5559.

Clear Cell Tumors of the Ovary – Rare Subtype of Ovarian Cancer, Sugiyama T., American Society of Clinical Oncology Educational Session, 2007 Annual Meeting, June 2, 2007.

RAD001 (Everolimus) delays tumor onset and progression in a transgenic mouse model of ovarian cancer; Mabuchi S et. al., Cancer Res. 2007 Mar 15;67(6):2408-13.

Lack of effective systemic therapy for recurrent clear cell carcinoma of the ovary; Crotzer DR, Gynecol Oncol. 2007 May;105(2):404-8. Epub 2007 Feb 9.

Overexpression and prognostic value of p53 and HER2/neu proteins in benign ovarian tissue and in ovarian cancer; Coronado Martín PJ et. al., Med Clin (Barc). 2007 Jan 13;128(1):1-6.

Ovarian clear cell adenocarcinoma: a continuing enigma; Tan DS et. al., J Clin Pathol. 2007 Apr;60(4):355-60. Epub 2006 Oct 3.

Adenovirus type 5 E1A gene therapy for ovarian clear cell carcinoma: a potential treatment strategy; Itamochi H et. al., Mol Cancer Ther. 2007 Jan;6(1):227-35. Epub 2007 Jan 11.

Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary; Takano M et. al., Oncol Rep. 2006 Dec;16(6):1301-6.

Treatment Issues in Clear Cell Carcinoma of the Ovary: A Different Entity?, Pectasides D, The Oncologist, Vol. 11, No. 10, 1089-1094, November 2006; doi:10.1634/theoncologist.11-10-1089.

Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience; Pectasides D et. al, Gynecol Oncol. 2006 Aug;102(2):285-91. Epub 2006 Mar 3.

Proliferative activity of early ovarian clear cell adenocarcinoma depends on association with endometriosis; Komiyama S, Aoki D, Katsuki Y, Nozawa S., Eur J Obstet Gynecol Reprod Biol. 2006 Jul;127(1):130-6. Epub 2006 Jan 27.

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging; Takano M, Br J Cancer. 2006 May 22;94(10):1369-74.

PTEN expression in clear cell adenocarcinoma of the ovary; Hashiguchi Y, Tsuda H, Inoue T, Berkowitz RS, Mok SC, Gynecol Oncol. 2006 Apr;101(1):71-5. Epub 2005 Nov 10.

Expression of hepatocyte nuclear factor-1beta (HNF-1beta) in clear cell tumors and endometriosis of the ovary; Kato N, Sasou S, Motoyama T, Mod Pathol. 2006 Jan;19(1):83-9.

Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer; Zorn KK, et. al., Clin Cancer Res. 2005 Sep 15;11(18):6422-30.

Complete response to irinotecan hydrochloride and nedaplatin in a patient with advanced ovarian clear cell carcinoma; Nishida M, International Journal of Clin Onc 2004 Oct.; 9(5): 403-405.

Overexpression of HER-2/neu is not a risk factor in ovarian clear cell adenocarcinoma; Tanabe H et. al., Gynecol Oncol. 2004 Sept; 94(3): 735-739.

Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease; Ho CM et. al., Gynecol Oncol. 2004 Jul;94(1):197-203.

Gene Expression Patterns in Ovarian Carcinomas; Schaner ME et. al., Mol. Bio. Cell 2003 Dec.; 14(11):4376-4386.

HER-2/neu expression in ovarian clear cell carcinomas; Iwamoto H, International J. Gynec Oncol 2003 Mar; 13(1): 28-31.

Evaluation of Monoclonal Humanized Anti-HER2 Antibody, Trastuzumab, in Patients With Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma With Overexpression of HER2: A Phase II Trial of the Gynecologic Oncology Group; Bookman MA et. al., J Clin Oncol, 2003 Jan; 21(2): 283-290

Phase II Trial of Irinotecan in Patients With Metastatic Epithelial Ovarian Cancer or Peritoneal Cancer; Bodurka DC, Journal of Clin Onc 2003 Jan; 21(2): 291-297.

HER2 Is Frequently Over-expressed in Ovarian Clear Cell Adenocarcinoma: Possible Novel Treatment Modality Using Recombinant Monoclonal Antibody against HER2, Trastuzumab; Fujimura M, Jpn. J. Cancer Res 2002 Nov.; 93: 1250-1257.

Gene Expression in Ovarian Cancer Reflects Both Morphology and Biological Behavior, Distinguishing Clear Cell from Other Poor-Prognosis Ovarian Carcinomas; Schwartz DR, Cancer Research 2002 Aug; 62, 4722-4729

Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary; Itamochi H, Obstet Gynecol. 2002 Aug;100(2):281-7.

Clear cell carcinoma of the ovary: a remarkable case; Giblin J, Fanucchi MP, McGuire WP, Am J Clin Oncol. 2001 Feb;24(1):99-100.

Camptothecin and mitomycin combination chemotherapy on ovarian clear cell carcinoma with multiple systemic metastases; Tanaka T, Umesaki N, Ogita S, Eur J Gynaecol Oncol. 2000;21(4):377-9.

A Pilot Study of CPT-11 and Cisplatin for Ovarian Clear Cell Adenocarcinoma; Adachi S et. al., Japanese Journal of Clin Oncol; 1999 June; 29(9): 434-437.

HER-2/neu amplification and overexpression in endometrial carcinoma; Rolitsky CD et. al., Int J Gynecol Pathol. 1999 Apr;18(2):138-43.

Chemotherapy for ovarian clear cell adenocarcinoma with irinotecan hydrochloride and mitomycin C; Umezawa S et. al., International Journal of Clin Onc 1996 Sept; 1(3): 157-162.

Germ Cell Ovarian Cancer

Sex Cord Stromal Ovarian Cancer

Angiogenesis Linked to Poor Survival in Patients With Rare Type of Ovarian Cancer – Drugs that block new blood vessel formation may improve outcomes of patients with sex cord-stromal tumors, M.D. Anderson Cancer Center News Release, Feb. 5, 2009 (Researchers from The University of Texas M. D. Anderson Cancer Center found that increased angiogenesis, or blood vessel formation, and vascular endothelial growth factor expression are associated with poor survival in women with sex cord-stromal ovarian tumors. This data was presented in a poster session).

Rare Forms of Ovarian Cancer

Fibrosarcoma

Small Cell Carcinoma